In its continuing studies of gene expression, Roche Bioscience of Palo Alto, California, on Thursday agreed to evaluate the GeneChip technology developed by Affymetrix.
Roche, which specializes in early clinical development of prescription drugs, will use Affymetrix instruments based on the GeneChip to monitor the effects of disease on genetic patterns. The GeneChip contains circuitry that mimics the signals sent along strands of human DNA.
The Santa Clara, California-based Affymetrix is developing instruments based on the chip that will allow researchers to gather genetic data for use in diagnosing and treating disease.
